Assessing Gene Expression and Methylation of KMT2D and IGF2 Genes in Patients with Non-Small Cell Lung Cancer

Cancer and clinical oncology Pub Date : 2018-02-18 DOI:10.5539/CCO.V7N1P55

A. Ahmadi, Hessamodin Ghasemi, S. Nooshin, Zoofa Zayani, S. Z. Karizi, M. Karimipoor

{"title":"Assessing Gene Expression and Methylation of KMT2D and IGF2 Genes in Patients with Non-Small Cell Lung Cancer","authors":"A. Ahmadi, Hessamodin Ghasemi, S. Nooshin, Zoofa Zayani, S. Z. Karizi, M. Karimipoor","doi":"10.5539/CCO.V7N1P55","DOIUrl":null,"url":null,"abstract":"Background: Aberrant promoter methylation of CpG islands is an important mechanism for regulation of gene expression. Recent data suggest that epigenetic abnormalities may occur very early in lung carcinogenesis. Systemic methylation changes may be a diagnostic marker for tumor development or prognosis. In this study, the expression and methylation of KMT2D and IGF2 genes were investigated in the lung cancer tissue compared to the adjacent normal tissue.Methods: The status of methylation of KMT2D and IGF2 genes were investigated in 30 patients with NSCLC after genomic DNA extraction using bisulfite treatment and MS-HRM method and the expression of these genes were checked by Real-Time PCR method in same samples.Results: For KMT2D gene, the expression and methylation level increased in 46.6% and 6.67% (respectively) for tumor samples comparison with normal samples (P>0.05). Also, for IGF2 gene 50% tumor samples overexpressed and 50% tumor samples showed that reduced expression comparison with the normal samples (P>0.05). In addition, 96.66% of tumor tissues did not show any change in methylation level for IGF2 gene promoter (P>0.05).Conclusion: This study showed that expression and methylation level of KMT2D and IGF2 genes did not change in NSCLC tumor samples compared to normal samples. However, this study was designed as a pilot study, and further investigations are required to confirm our findings.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"7 1","pages":"55"},"PeriodicalIF":0.0000,"publicationDate":"2018-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V7N1P55","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5539/CCO.V7N1P55","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Background: Aberrant promoter methylation of CpG islands is an important mechanism for regulation of gene expression. Recent data suggest that epigenetic abnormalities may occur very early in lung carcinogenesis. Systemic methylation changes may be a diagnostic marker for tumor development or prognosis. In this study, the expression and methylation of KMT2D and IGF2 genes were investigated in the lung cancer tissue compared to the adjacent normal tissue.Methods: The status of methylation of KMT2D and IGF2 genes were investigated in 30 patients with NSCLC after genomic DNA extraction using bisulfite treatment and MS-HRM method and the expression of these genes were checked by Real-Time PCR method in same samples.Results: For KMT2D gene, the expression and methylation level increased in 46.6% and 6.67% (respectively) for tumor samples comparison with normal samples (P>0.05). Also, for IGF2 gene 50% tumor samples overexpressed and 50% tumor samples showed that reduced expression comparison with the normal samples (P>0.05). In addition, 96.66% of tumor tissues did not show any change in methylation level for IGF2 gene promoter (P>0.05).Conclusion: This study showed that expression and methylation level of KMT2D and IGF2 genes did not change in NSCLC tumor samples compared to normal samples. However, this study was designed as a pilot study, and further investigations are required to confirm our findings.

查看原文本刊更多论文

评估非小细胞肺癌患者KMT2D和IGF2基因的表达和甲基化

背景：CpG岛异常启动子甲基化是基因表达调控的重要机制。最近的数据表明，表观遗传学异常可能在肺癌发生的早期就发生了。系统甲基化变化可能是肿瘤发展或预后的诊断标志。在本研究中，与邻近的正常组织相比，研究了肺癌组织中KMT2D和IGF2基因的表达和甲基化。方法：采用亚硫酸氢盐处理和MS-HRM方法对30例NSCLC患者基因组DNA提取后KMT2D和IGF2基因甲基化的情况进行研究，并用实时PCR方法检测这些基因在同一样本中的表达。结果：对于KMT2D基因，肿瘤样品的表达和甲基化水平与正常样品相比分别增加了46.6%和6.67%（P>0.05）。此外，对于IGF2基因，50%的肿瘤样品过表达和50%的肿瘤样本显示与正常样品相比较表达降低（P>0.05），96.66%的肿瘤组织IGF2基因启动子甲基化水平没有变化（P>0.05）。然而，这项研究是作为一项试点研究设计的，需要进一步的调查来证实我们的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer and clinical oncology

自引率

0.00%

发文量